Anorexia in Adolescence Clinical Trial
— FEDOfficial title:
Finding Treatments for Eating Disorders
Currently, Family Based Treatment (FBT) is the leading evidence-based, manualized treatment for adolescents with anorexia nervosa (AN). FBT emphasizes parental involvement in addressing disordered eating by supporting the child in eating and refeeding to achieve a healthy body weight and independent eating. Based on multiple RCTs, 50% of AN patients who receive FBT recover, and those who do not are more likely to develop a chronic illness. Research demonstrates that weight gain of less than 2.3kg (4.8 pounds) by week 4 of FBT predicts that 75% of adolescents with AN will not achieve weight restoration by the end of treatment. FBT works in part by reducing the avoidance of food and increasing the exposure to food triggers, like the treatment of anxiety disorders and obsessive-compulsive disorder (OCD). Thus, researchers postulate that anxiety may be a negative predictor of FBT treatment outcome in the early phase of FBT. In addition, elevated baseline anxiety has been shown to be associated with poorer outcomes at end of treatment and may also impact the likelihood of early response. To improve clinical response, we need to develop viable biological treatment targets (i.e., brain areas implicated in anxiety) that could be combined with FBT. Such targets can be defined by 1) initially targeting brain areas that mediate symptoms hindering treatment response (i.e., anxiety), and 2) looking at changes in brain chemistry and function. Thus, repetitive transcranial magnetic stimulation (rTMS) could be an alternative and promising treatment approach for adolescents with AN who do not respond to Phase 1 of FBT. Using rTMS, we can target the brain areas implicated in anxiety in people with anorexia and modulate that activity to reduce symptoms, and thus, facilitate response to FBT. Several studies have shown the rTMS to the right dorsolateral prefrontal cortex (DLPFC) is effective in reducing anxiety across a range of neuropsychiatric disorders. Therefore, it is possible that stimulating the right DLPFC could facilitate treatment efficacy of FBT in youth with AN. Additional explorations of the connections between, and neurochemistry of, the right DLPFC and those mediating emotion in the brain (e.g., amygdala) could aid in our understanding of the networks impeding effective treatment responses and allow for more tailored, precision targeting with TMS.
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | May 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 18 Years |
Eligibility | Inclusion Criteria: - Diagnosis of Anorexia Nervosa (AN) by medical and psychiatric assessment at the Calgary Eating Disorder Program. - English fluency (i.e., able to consent and assent to the study) - Aged 12 to 18 - Medically stable - Medications for AN or psychiatric disorders are allowed if the dose has been stable for six weeks with adequate compliance, with a commitment to not change medication/dosage during the trial period. If a medication change occurs, the research team will document this. Exclusion Criteria: - Diagnosis of mania or psychosis - Impediments to TMS or MRI (i.e., braces, having non-MRI compatible metals in the body) - Diagnosis of Autism Spectrum Disorder - Diagnosis of post-concussive syndrome - Plans to move/be unavailable for clinic visits for 6 to 9 months after the start of treatment |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Children's Hospital | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Calgary | University of Alberta |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Outcome - Change in anxiety as measured by the Multidimensional Anxiety Scale for Children (MASC-2) from baseline to 6 weeks. | Change in anxiety as measured by the Multidimensional Anxiety Scale for Children (MASC-2) from baseline to 6 weeks in early non-responders to FBT receiving active rTMS as compared to those receiving sham-rTMS. | Six weeks | |
Primary | Primary Outcome - Number of subjects achieving weight restoration | Number of early non-responders to FBT who achieve weight restoration (i.e., >95% of expected mean BMI) at the end of active rTMS of the DLPFC treatment as compared to those receiving sham-rTMS. | Six weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06244576 -
Emotional Dysregulation, Maladaptive Overcontrol in Anorexia - Effect of Radically Open Dialectical Behaviour Therapy
|
N/A | |
Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Recruiting |
NCT05057000 -
Effect of Aerobic Exercises and Nutrition In Adolescent Girls With Anorexia
|
N/A | |
Recruiting |
NCT05674266 -
New Treatment Perspectives in Adolescents With Anorexia Nervosa: the Efficacy of Non-invasive Brain-directed Treatment
|
N/A | |
Recruiting |
NCT05418075 -
Evaluation of the Effectiveness of Add-on Hometreatment to Family Based Therapy in Adolescent Anorexia Nervosa.
|
N/A | |
Recruiting |
NCT06097247 -
Family Functioning and Adverse Side Effects of Family-based Therapy for Anorexia Nervosa
|
||
Recruiting |
NCT05235867 -
Secretin in Refeeding
|
||
Terminated |
NCT05073679 -
Oral Naltrexone In Pediatric Eating Disorders
|
Phase 2/Phase 3 |